<DOC>
	<DOC>NCT00768989</DOC>
	<brief_summary>The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).</brief_summary>
	<brief_title>Phase IIB Pilot of Atazanavir + Raltegravir</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Human Immunodeficiency Virus (HIV)1 positive status HIV ribonucleic acid (RNA) level &gt;=5000 copies/mL Antiretroviral treatmentnaive Absolute Cluster of Differentiation 4 (CD4) cell count meeting 1 of the following criteria: &lt;350 cells/mm^3 Screening CD4 &gt;=350 and &lt;=500 cells/mm^3 ONLY if at least 1 of the following conditions apply: Screening HIV RNA level &gt;100,000 copies/mL, or CD4 decline &gt;50100 cells/mm^3/year, or Age &gt;=55 years Any CD4 cell count, if participant has a history of an acquired immune deficiency syndromedefining illness Medically stable Screening HIV genotype showing resistance to any component of the study regimen (Atazanavir, Raltegravir, Tenofovir/Emtricitabine) Hepatitis B or hepatitis C coinfection History of or current cardiac disease Electrocardiogram findings: PR Interval &gt;260 msec (severe 1st degree atrioventricular block) QRS Interval &gt;120 msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Combination Therapy</keyword>
</DOC>